Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 9/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CASR | P41180 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9640850 | 0.88 | ADRB2 (0.56) | ADRB3ADRB1ADRB2LMNA | |
| Hydrochloric Acid SCHEMBL9640639 | 0.86 | LMNA (0.57) | ADRB3ADRB1ADRB2SLC2A1LMNA | |
| SCHEMBL9641345 | 0.85 | ADRB2 (0.65) | ADRB3ADRB1ADRB2SLC2A1LMNA | |
| SCHEMBL10893060 | 0.83 | ADRB3 (0.58) | ADRB3ADRB1ADRB2SLC2A1CASR | |
| SCHEMBL7838707 | 0.83 | ADRB3 (0.47) | ADRB3ADRB1ADRB2SLC2A1LMNA | |
| Fepradinol SCHEMBL151235 | 0.82 | KDM4E (0.55) | ADRB3ADRB1ADRB2LMNA | |
| Fepradinol SCHEMBL29454386 | 0.81 | KDM4E (0.53) | ADRB1ADRB2LMNA | |
| SCHEMBL9467996 | 0.81 | ADRB3 (0.59) | ADRB3ADRB1ADRB2SLC2A1CASR | |
| SCHEMBL10891709 | 0.81 | SLC2A1 (0.53) | ADRB3ADRB1ADRB2SLC2A1 | |
| Fepradinol SCHEMBL1649187 | 0.80 | KDM4E (0.52) | ADRB3ADRB1ADRB2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306162-A1 | Treatment of Inflammatory Disorders and Pain | SOSEI R&D LTD. (GB) | 2008-12-11 | — | — | US | disclosed |
| EP-1896393-A1 | THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | Sosei R&D Ltd. (GB) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007003896-A1 | THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | SOSEI R & D LTD. (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306162-A1 | Treatment of Inflammatory Disorders and Pain | HRH3, OPRL1, HRH2 | ADRB3 95/4885ADRB1 198/4885ADRB2 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.